OncoMatch/Clinical Trials/NCT06221683
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
Is NCT06221683 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for aml, childhood.
Treatment: Homoharringtonine · Cytarabine · Etoposide · Venetoclax · Mitoxantrone hydrochloride liposome · Recombinant Human Granulocyte Colony-Stimulating Factor · Idarubicin Hydrochloride · Sorafenib · Gilteritinib · Avapritinib — The goal of this clinical trial is to estimate the rate (probability) of complete remission or complete remission with incomplete count recovery (CR/CRi) with negative MRD after induction I and II, event-free survival (EFS), and cumulative incidence (probability) of relapse (CIR), in patients receiving molecular/precision medicine and MRD-driven remission inductions, and to assess secondarily if there is an improvement over the AML2018 protocol.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic chemotherapy
Exception: hydroxyurea or cytarabine before diagnosis, cytarabine ≤ 5 days and total dose ≤ 500 mg/m2
Patients who have used hydroxyurea or cytarabine before diagnosis, but the dosage of cytarabine does not exceed 5 days, and the total dose does not exceed 500 mg/m2 (50 mg/m2, q12h × 5d)
Cannot have received: chemotherapy, radiotherapy, or immunotherapy
Exception: temporary only, not systemic therapy per protocol
Only temporary chemotherapy, radiotherapy, or immunotherapy, but not systematic treatment according to the treatment plan
Cannot have received: chemotherapy, radiotherapy, or immunotherapy
Exception: temporary only, not systemic therapy per protocol
Temporary chemotherapy, radiotherapy, or immunotherapy only, not systemic therapy per protocol
Lab requirements
Kidney function
creatinine clearance ≥50ml/min
Liver function
Tbil≤2×ULN, ALT/AST≤3×ULN
Cardiac function
NYHA grading<3; SaO2>92%
Liver function：Tbil≤2×ULN, ALT/AST≤3×ULN, creatinine clearance ≥50ml/min；Cardiac NYHA grading<3；SaO2>92%;
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06221683 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 18 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages